title: Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms.
abstract: BACKGROUND
  Body surface distribution and magnitude of ST segment elevation and their reflection in 12-lead ECGs have not been clarified in Brugada syndrome.
  
  
  RESULTS
  Eighty-seven-lead body surface potential mapping and 12-lead ECGs were recorded simultaneously in 25 patients with Brugada syndrome and 40 control patients. The amplitude of the ST segment 20 msec after the end of QRS (ST20) was measured from all 87 leads, and an ST isopotential map was constructed. The maximum ST elevation (maxST20) was distributed in an area of the right ventricular outflow tract in all Brugada patients, and it was larger than that in control patients (0.37 +/- 0.13 vs 0.12 +/- 0.04 mV; P < 0.0005). The maximum was observed on the level of the parasternal fourth intercostal space, on which the V1 and V2 leads of the standard 12-lead ECG were located, in 18 of the 25 Brugada patients in whom typical coved- or saddleback-type ST elevation was seen in leads V1 and V2. The maximum was located on the second intercostal space in the remaining seven Brugada patients in whom only a mild saddleback-type ST elevation was seen in leads V1 and V2 of the 12-lead ECG. Typical ST segment elevation was recognized in leads V1 and V2, which were recorded on the second or third intercostal space. ST elevation in Brugada patients was dramatically normalized by isoproterenol, a beta-adrenergic agonist (maxST20 = 0.17 +/- 0.08 mV; P < 0.0005 vs control conditions), and accentuated by disopyramide, an Na+ channel blocker (maxST20 = 0.50 +/- 0.15 mV; P < 0.0005 vs control conditions), without any change in the location of the maxST20.
  
  
  CONCLUSIONS
  Our data indicate that recordings of leads V1-V3 of the 12-lead ECG on the parasternal second or third intercostal space would be helpful in diagnosing suspected patients with Brugada syndrome. The data suggest that Na+ channel blockers are capable of accentuating ST elevation in leads V1-V3.
authors.affiliation: Department of Internal Medicine, National Cardiovascular Center, Suita, Osaka, Japan. wshimizu@hsp.ncvc.go.jp
authors.forename: W
authors.initials: W
authors.lastname: Shimizu
authors.forename: K
authors.initials: K
authors.lastname: Matsuo
authors.forename: M
authors.initials: M
authors.lastname: Takagi
authors.forename: Y
authors.initials: Y
authors.lastname: Tanabe
authors.forename: T
authors.initials: T
authors.lastname: Aiba
authors.forename: A
authors.initials: A
authors.lastname: Taguchi
authors.forename: K
authors.initials: K
authors.lastname: Suyama
authors.forename: T
authors.initials: T
authors.lastname: Kurita
authors.forename: N
authors.initials: N
authors.lastname: Aihara
authors.forename: S
authors.initials: S
authors.lastname: Kamakura
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018780:Body Surface Potential Mapping / Q000187:drug effects / Q000379:methods; D002037:Bundle-Branch Block / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D003937:Diagnosis, Differential; D004206:Disopyramide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D007545:Isoproterenol / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D014693:Ventricular Fibrillation / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D000318:Adrenergic beta-Agonists; D000889:Anti-Arrhythmia Agents; D004206:Disopyramide; D007545:Isoproterenol